Cargando…

P712: SOLUBLE PD-L1 PREDICT POOR OVERALL SURVIVAL AND DISEASE PROGRESSION IN PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME

Detalles Bibliográficos
Autores principales:	Yang, Xingcheng, Zhang, Xiaoying, Zhang, Yicheng, Wei, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429541/ http://dx.doi.org/10.1097/01.HS9.0000969752.58334.fd

Ejemplares similares

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
por: Yang, Xingcheng, et al.
Publicado: (2022)

Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
por: Zhang, Xiaoying, et al.
Publicado: (2023)

712. Neurocysticercosis at a Large Academic Center in the USA
por: Ramanathan, Maya, et al.
Publicado: (2021)

Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes
por: Sotirova, Tatjana, et al.
Publicado: (2014)

Chemical carcinogenesis by 7,12-dimethylbenzanthracene in balb/c mice
por: Tedardi, Marcello V, et al.
Publicado: (2013)

P966: SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM
por: Fridberg, Gil, et al.
Publicado: (2023)

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
por: Chen, Cunte, et al.
Publicado: (2021)

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
por: Iivanainen, Sanna, et al.
Publicado: (2019)

Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes
por: Maurya, Nehakumari, et al.
Publicado: (2022)

Soluble CD30 is a new biomarker to predict two-year overall survival of adult T cell leukemia/lymphoma patients
por: Pornkuna, Ratiorn, et al.
Publicado: (2014)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
por: Széles, Ádám, et al.
Publicado: (2022)

PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas
por: Zhang, Shuang, et al.
Publicado: (2020)

Increased PD-1(+)Foxp3(+) γδ T cells associate with poor overall survival for patients with acute myeloid leukemia
por: Zheng, Jiamian, et al.
Publicado: (2022)

Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes
por: Shi, Cong, et al.
Publicado: (2022)

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes
por: Kuszczak, Bartłomiej, et al.
Publicado: (2023)

Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis
por: Ye, Jiabu, et al.
Publicado: (2020)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer
por: Fang, Wenfeng, et al.
Publicado: (2017)

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer
por: Marinelli, Oliviero, et al.
Publicado: (2020)

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer
por: Siddiqui, Bilal A., et al.
Publicado: (2022)

S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes
por: Cheng, Pinyang, et al.
Publicado: (2019)

High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer
por: Tan, Lei, et al.
Publicado: (2020)

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015)

712. Risk of Infective Endocarditis after Transcatheter Aortic Valve Replacement in Patients with Bloodstream Infection: A Population-Based Study
por: Talha, Khawaja M, et al.
Publicado: (2020)

Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer
por: Gu, Xiaobin, et al.
Publicado: (2019)

Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer
por: Shen, Li-Fang, et al.
Publicado: (2020)

Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort
por: Díaz-Casas, Sandra Esperanza, et al.
Publicado: (2022)

Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis
por: Zhou, Zhirui, et al.
Publicado: (2021)

Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2021)

Prevalence of NRAS Mutation, PD‐L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas
por: Wang, Hai‐Yun, et al.
Publicado: (2019)

Simultaneous high PD-L1 and low VEGFR2 expression is associated with better overall survival in rectal cancer
por: Ding, Yun, et al.
Publicado: (2021)

P790: THE EXPRESSION LEVEL OF WT1 MRNA IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) PROGRESSING TO MYELODYSPLASTIC SYNDROME (MDS)
por: Ye, X., et al.
Publicado: (2022)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

P1661: THROMBOPATHY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND AUTOIMMUNE DISEASE
por: Garcia Perez, E., et al.
Publicado: (2022)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
por: Wu, De‐hong, et al.
Publicado: (2019)

Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome
por: Shi, Cong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5gq6mh4mc5b8h4luoqvlpn2vc3